Table 2 Current anthropometric feature, pulmonary involvement, disease status and drug treatment of patients with dermatomyositis and antisynthetase syndrome, and control group (at the time of analysis)

Current age (years)^b

48.1 ± 9.4

46.9 ± 10.2

47.76 ± 4.44

0.993

0.960

0.935

Time of disease (years)

7.9 ± 4.5

6.7 ± 3.9

–

–

–

0.785

Body mass index (kg/m²)

29.2 (23.9–35.2)

32.2 (31.8–35.6)

28.5 (25.5–30.2)

> 0.999

0.056

0.189

Pulmonary involvement (%)

1 (7.7)

3 (33.3)

–

–

–

0.167

Disease status^b

–

–

–

HAQ (0.00–3.00)

0.06 (0.00–0.34)

0.50 (0.00–0.75)

–

–

–

0.451

MMT-8 (0–80)

80 (80–80)

80 (80–80)

–

–

–

> 0.999

Patients’ VAS (0–10)

0.0 (0.0–1.0)

0.0 (0.0–0.0)

–

–

–

0.408

Physician’ VAS (0–10)

0.0 (0.0–0.0)

0.0 (0.0–0.0)

–

–

–

0.544

MYOACT (0–60)

0.0 (0.0–0.0)

0.0 (0.0–0.0)

–

–

–

0.746

Creatine phosphokinase (U/L)

97 (70–149)

141 (85–204)

–

–

–

0.180

Treatment

–

–

–

Prednisone

–

–

–

Current use (%)

5 (29.4)

4 (44.4)

–

–

–

> 0.999

Dose (mg/day)

0.0 (0.0–7.5)

0.0 (0.0–10.0)

–

–

–

0.337

IS or immunobiological (%)

–

–

–

Current use of one or more

12 (92.3)

9 (100.0)

–

–

–

> 0.999

Azathioprine

5 (29.4)

5 (55.6)

–

–

–

0.666

Methotrexate

6 (46.2)

3 (33.3)

–

–

–

0.674

Others^a

2 (15.4)

5 (55.6)

–

–

–

0.290

Rituximab

0

1 (11.1)

–

–

–

–